Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma

Cetin B., Afsar B., DEĞER S. M., IŞIK GÖNÜL İ., Gumusay O., ÖZET A., ...More

INTERNATIONAL UROLOGY AND NEPHROLOGY, vol.46, no.6, pp.1081-1087, 2014 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 46 Issue: 6
  • Publication Date: 2014
  • Doi Number: 10.1007/s11255-013-0613-x
  • Journal Name: INTERNATIONAL UROLOGY AND NEPHROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1081-1087
  • Keywords: Metastatic renal cell carcinoma, Anemia, Variability, VEGF-targeted therapy, LEVEL VARIABILITY, INTERFERON-ALPHA, HOSPITALIZATION, CANCER, ANEMIA
  • Dokuz Eylül University Affiliated: No

Abstract

There are no robust data on hemoglobin (Hb), lactate dehydrogenase (LDH), and calcium variability for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy. We aim to evaluate prognostic implications of Hb, LDH, and calcium variability and establish a novel risk stratification model in RCC patients receiving targeted therapies.